alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the trea...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Zhang, Jian, Shi, Shengliang, Zhang, Yueling, Luo, Jiefeng, Xiao, Yousheng, Meng, Lian, Yang, Xiaobo
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2017
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6486233/
https://ncbi.nlm.nih.gov/pubmed/29178444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010968.pub2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars